| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.8 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0094 | 0.8 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.0094 | 0.8 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |